-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference
-- Annual "From Laboratory to Clinic" conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine --
-- PAS002 is a proprietary DNA vaccine construct encoding GlialCAM --
MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced it will present the preclinical proof of concept study results of its tolerizing vaccine program in multiple sclerosis ("MS") on August 30th at the international conference "From Laboratory to Clinic: Medicine after COVID" held at Trinity College, Oxford University, United Kingdom.
From Laboratory to Clinic is an annual translational research conference established in 1984 that brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. During the Symposium, Pasithea's Chairman, National Academy of Sciences Professor Lawrence Steinman, will be giving the opening keynote lecture. Other speakers will include Dr. Carola Vinuesa, Professor at the Francis Crick Institute in London; Dr. Gali Alter, Professor of medicine at Harvard Medical School; Dr. Jeffrey Ravetch, Professor and head of the Laboratory of Molecular Genetics and Immunology at the Rockefeller University and Dr. Anne Schaefer, Vice-chair of Neuroscience at the Icahn School of Medicine at Mount Sinai.
"We look forward to presenting our data at this important international conference alongside other world recognized leading authorities in immunology and immunotherapy. The study results support the Company's commitment to the program and move us further along our path to uncover new and effective treatments for neurological disorders," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
Date: | Tuesday, August 30, 2022 |
Time: | 9:00 a.m. - 9:50 a.m. ET |
Conference details.
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Forward Looking Statements
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
-- Annual "From Laboratory to Clinic" conference, held at Trinity College, Oxford University, explores latest discoveries in immunology and molecular medicine --
-- PAS002 is a proprietary DNA vaccine construct encoding GlialCAM --
一年一度的“从实验室到临床”会议在牛津大学三一学院举行,探讨免疫学和分子医学的最新发现--
--PAS002是一种编码GlialCAM的专有DNA疫苗构建体--
MIAMI BEACH, Fla., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced it will present the preclinical proof of concept study results of its tolerizing vaccine program in multiple sclerosis ("MS") on August 30th at the international conference "From Laboratory to Clinic: Medicine after COVID" held at Trinity College, Oxford University, United Kingdom.
佛罗里达州迈阿密海滩,2022年8月18日(环球通讯社)--专注于研究和发现治疗精神和神经疾病的新的有效疗法的生物技术公司帕西西亚治疗公司(纳斯达克代码:KTTA)今天宣布,它将于8月30日提交其多发性硬化症(MS)耐受疫苗计划的临床前概念证明研究结果这是在英国牛津大学三一学院举行的《从实验室到临床:新冠肺炎后的医学》国际会议上。
From Laboratory to Clinic is an annual translational research conference established in 1984 that brings together basic scientists, clinicians, and industry researchers to explore how the latest discoveries in immunology and molecular medicine can be applied to improve clinical medicine. During the Symposium, Pasithea's Chairman, National Academy of Sciences Professor Lawrence Steinman, will be giving the opening keynote lecture. Other speakers will include Dr. Carola Vinuesa, Professor at the Francis Crick Institute in London; Dr. Gali Alter, Professor of medicine at Harvard Medical School; Dr. Jeffrey Ravetch, Professor and head of the Laboratory of Molecular Genetics and Immunology at the Rockefeller University and Dr. Anne Schaefer, Vice-chair of Neuroscience at the Icahn School of Medicine at Mount Sinai.
从实验室到临床是一个成立于1984年的年度翻译研究会议,聚集了基础科学家、临床医生和行业研究人员,探讨如何将免疫学和分子医学的最新发现应用于改善临床医学。在研讨会期间,Pasithea主席、美国国家科学院教授Lawrence Steinman将作开幕主旨演讲。其他讲者包括伦敦Francis Crick Institute教授Carola Vinuesa博士、哈佛医学院医学教授Gali Alter博士、洛克菲勒大学分子遗传学和免疫学实验室主任Jeffrey Ravetch博士和西奈山Icahn医学院神经科学副主席Anne Schaefer博士。
"We look forward to presenting our data at this important international conference alongside other world recognized leading authorities in immunology and immunotherapy. The study results support the Company's commitment to the program and move us further along our path to uncover new and effective treatments for neurological disorders," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea.
Pasithea公司首席执行官蒂亚戈·里斯·马奎斯博士说:“我们期待着在这次重要的国际会议上与其他世界公认的免疫学和免疫疗法的领先权威一起展示我们的数据。研究结果支持了公司对该计划的承诺,并推动我们在发现治疗神经疾病的新的有效疗法的道路上更进一步。”
Date: | Tuesday, August 30, 2022 |
Time: | 9:00 a.m. - 9:50 a.m. ET |
日期: | 2022年8月30日(星期二) |
时间: | 上午9点-上午9:50外星人 |
Conference details.
会议详细信息。
About Pasithea Therapeutics Corp.
Pasithea治疗公司简介
Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders. With an experienced team of experts in the fields of neuroscience and psychopharmacology, Pasithea is developing new molecular entities for the treatment of psychiatric and neurological disorders. Pasithea is also focused on addressing the needs of patients currently suffering with mental illness by providing access to IV ketamine infusions both in clinics and in-home settings.
Pasithea治疗公司是一家美国生物技术公司,专注于研究和发现治疗精神和神经疾病的新的有效疗法。Pasithea拥有一支在神经科学和精神药理学领域经验丰富的专家团队,正在开发用于治疗精神和神经疾病的新分子实体。Pasithea还专注于通过在诊所和家庭环境中提供静脉注射氯胺酮来满足目前患有精神疾病的患者的需求。
Forward Looking Statements
前瞻性陈述
This press release contains statements that constitute "forward-looking statements." Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company's filings with the SEC. Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.
本新闻稿包含构成“前瞻性陈述”的陈述。前瞻性陈述受许多条件的制约,其中许多条件不在公司的控制范围之内。虽然公司相信这些前瞻性陈述是合理的,但不应过度依赖任何此类前瞻性陈述,这些前瞻性陈述是基于公司在本新闻稿发布之日所掌握的信息。这些前瞻性陈述是基于当前的估计和假设,会受到各种风险和不确定性的影响,包括但不限于公司提交给美国证券交易委员会的报告中陈述的风险和不确定性。因此,实际结果可能会有很大不同。除法律要求外,本公司不承担在本新闻稿发布之日后因新信息、未来事件或其他原因而更新这些陈述的义务。
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis Marques
Chief Executive Officer
E: tiago@pasithea.com
Pasithea治疗公司联系人
蒂亚戈·里斯·马奎斯博士
首席执行官
电子邮件:tiago@pasithea.com
Pasithea Therapeutics Corp. Investor Relations
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Pasithea治疗公司投资者关系
丽莎·M·威尔逊
现场通信公司
T: 212-452-2793
电子邮箱:lwilson@insiteconi.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧